Biotech · Private company
Astellas Institute for Regenerative Medicine
Track this companyFree. Adds Astellas Institute for Regenerative Medicine to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial CellsPhase 2 · Macular Degenerative DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- MA09-hRPEPhase 2 · Stargardt's Macular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- MA09-hRPEPhase 2 · Dry Age Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AcyclovirPhase 1 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ASP2020Phase 1 · Stargardt DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ASP7317Phase 1 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- NystatinPhase 1 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- tacrolimusPhase 1 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- trimethoprim-sulfamethoxazolePhase 1 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- MA09-hRPEAge-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye ConditionsPHASE1 · RECRUITING · started Aug 14, 2026ClinicalTrials.gov NCT07734064 · fetched Nov 12, 2026
- A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular DegenerationPHASE1 · RECRUITING · started Jul 13, 2018ClinicalTrials.gov NCT03178149 · fetched Nov 12, 2026
- A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell TherapyPHASE1_PHASE2 · ENROLLING_BY_INVITATION · started Jan 8, 2018ClinicalTrials.gov NCT03167203 · fetched Nov 12, 2026
- Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMDCOMPLETED · started Feb 25, 2013ClinicalTrials.gov NCT02463344 · fetched Nov 12, 2026
- Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy PatientsCOMPLETED · started Jul 11, 2012ClinicalTrials.gov NCT02445612 · fetched Nov 12, 2026
- Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular DystrophyPHASE1_PHASE2 · COMPLETED · started Jun 16, 2011ClinicalTrials.gov NCT01345006 · fetched Nov 12, 2026
- Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular DegenerationPHASE1_PHASE2 · COMPLETED · started Jun 9, 2011ClinicalTrials.gov NCT01344993 · fetched Nov 12, 2026